PAQ Therapeutics is a biotechnology company focused on leveraging targeted protein degradation to suppress oncogenic KRAS signaling in cancer. Its lead candidates include PT0253, a KRAS G12D degrader, and PT0511, a pan-KRAS degrader designed to address multiple oncogenic KRAS variants. The company has initiated a first-in-human, open-label Phase 1 trial of PT0511 to evaluate safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in patients with KRAS-altered solid tumors. Proceeds from recent financing will also support the ongoing Phase 1 development of PT0253. PAQ’s platform aspires to achieve deep, selective tumor suppression while maintaining favorable safety and combinability profiles, potentially overcoming limitations of current KRAS or pan-RAS inhibitor therapies. The firm’s total Series B capital now stands at $77 million, providing a strengthened balance sheet to advance multiple clinical programs.

Total raised

$146M

Funding rounds

3

Latest round

Series B

Latest activity

Jan 2026